Dr. Simone Schmitt
Head Antibody Development
Simone Schmitt joined Memo Therapeutics AG from Delenex Therapeutics AG, a biotech company focused on the development of single chain antibodies for the treatment of inflammatory diseases. One of her major achievements during her tenure at Delenex was the discovery and engineering of single chain antibody DLX2681 with an affinity in the sub-picomolar range. She is a co-inventor on two patent applications that issued from her work.
Dr. Schmitt is an experienced protein biochemist and molecular biologist. She did her PhD with Prof. Dr. Dr. Walter Neupert at LMU, Munich and postdoctoral work with Prof. Dr. Kai Johnsson at EPFL, Lausanne.